BRAF and metastatic melanoma: Considering the subset of treated patients, we also found that the level of expression of BRAF V600E did not predict response or outcome to BRAF inhibitor therapy in metastatic melanoma patients, and these results confirmed what Wilmott et al. [10] had previously found.